Colorcon Ventures
VC Fund
Colorcon Ventures is a corporate venture fund of Colorcon Inc.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Colorcon Ventures invests in
Stages Colorcon Ventures invests in
Countries Colorcon Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ali Rajabi-Siahboom
|
|||
4 more contacts available
Investment Focus
Industry
- Biotechnology 4 (36%)
- Health Care 3 (27%)
- Life Science 3 (27%)
- Medical 2 (18%)
- Nutrition 2 (18%)
Stage
- Series A 4 (36%)
- Funding Round 2 (18%)
- Seed 1 (9%)
- Series B 1 (9%)
- Series C 1 (9%)
Country
- United States 5 (45%)
- Israel 1 (9%)
- United Kingdom 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ali Rajabi-Siahboom
Vice President, Chief Innovation Officer
|
Vice President, Chief Innovation Officer | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Phytolon
|
Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability | $23.6M / Series B / May 26, 2026 | |
|
Phytolon
|
Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability | Aug 13, 2025 | |
Syntis Bio
|
Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability. | $33M / Series A / Jul 01, 2025 | |
Vedanta Biosciences
|
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | Venture - Series Unknown / Feb 22, 2024 | |
MEND
|
MEND is a life sciences company with a mission to help people heal and live their healthiest. The company is currently researching and developing targeted clinical nutrition and medical food interventions to enhance patient outcomes, from injury and surgery to aging and physical performance. MEND has been adopted by numerous hospitals, healthsystems, professional sports teams across all major leagues, and the elite forces of the US Military. The company is headquartered in New York City. | $16.5M / Series A / Jun 06, 2023 | |
|
Syntis Bio
|
Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability. | $15.4M / Seed / Jan 17, 2023 | |
Apprentice.io
|
Apprentice is The Manufacturing AI Company. Since 2014 we've built intelligent, mission-critical systems that empower teams to automate workflows they never thought possible. Our proprietary AI model, Apprentice 4.1, is specifically trained and constrained for manufacturing—ensuring strict compliance and human-in-the-loop accountability.Apprentice 4.1 can be deployed as a stand-alone AI agent, or natively embedded within our next-gen Manufacturing Suite. From our Manufacturing Execution System (MES) and Laboratory Execution System (LES) to our Connected Manufacturing Network (CMN) and Manufacturing Intelligence (Analytics), Apprentice provides a complete suite of applications to run 24/7 operations and drive significant throughput and margin improvement.Backed by $207 million in venture funding, our platform is trusted by the world's leading manufacturers—including Moderna, Catalent and Gilead—to execute over 30 million requests per month. | $100M / Series C / Jan 19, 2022 | |
VeriSIM Life
|
VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials. VeriSIM offers a range of translational-based solutions, customized for the pre-clinical and clinical programs. These offerings are all centered around their proven and validated BIOiSIMTM platform for small molecules, largemolecules, and viruses. | $15M / Series A / Jan 13, 2022 | |
|
VeriSIM Life
|
VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials. VeriSIM offers a range of translational-based solutions, customized for the pre-clinical and clinical programs. These offerings are all centered around their proven and validated BIOiSIMTM platform for small molecules, largemolecules, and viruses. | $15M / Series A / Jan 13, 2022 | |
Nourished
|
Nourished is an award-winning tech start-up disrupting the nutrition industry with their 3D-printed vitamin stacks, which are completely tailor-made to each individual user. With their patented 3D printing manufacturing techniques and unique vegan encapsulation formula, Nourished is able to combine seven different high-impact nutrients, superfoods,and vitamins into one delicious gummy stack. Using 100% plastic-free packaging and only premium, sugar-free, and vegan ingredients. Nourished is as good for the Earth as it is for their customers. | Oct 12, 2021 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Colorcon Ventures invest in?
Colorcon Ventures invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Funding Round stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Colorcon Ventures?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Colorcon Ventures?
The team at Colorcon Ventures includes Ali Rajabi-Siahboom (Vice President, Chief Innovation Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
